Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KHK2823
- Development stage
- Discontinued
- Lead developer
- Kyowa Kirin
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KHK2823 is a fully human monoclonal antibody that targets CD123 (interleukin-3 receptor alpha chain), which is overexpressed on leukemic stem cells in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). By binding to and neutralizing CD123, KHK2823 aims to selectively target cancerous cells while sparing normal cells. The drug was developed for the treatment of AML and MDS but its development has been discontinued[1][2][4][5].
- Other names
- anti-cd123 monoclonal antibody khk2823anti-cd-123 monoclonal antibody khk2823anti-cd 123 monoclonal antibody khk2823
02
Targets
IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on KHK2823.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KHK2823.